4 research outputs found
Supplementary Material for: High Intraperitoneal Interleukin-6 Levels Predict Peritonitis in Peritoneal Dialysis Patients: A Prospective Cohort Study
<b><i>Background:</i></b> To evaluate the predictive value of dialysate interleukin-6 (IL-6) representing local subclinical intraperitoneal inflammation for the development of peritonitis in continuous ambulatory peritoneal dialysis (CAPD) patients. <b><i>Methods:</i></b> Stable prevalent CAPD patients were enrolled in this prospective study. IL-6 concentration in the overnight effluent was determined and expressed as the IL-6 appearance rate (IL-6AR). Patients were divided into 2 groups according to the median of IL-6AR and prospectively followed up until the first episode of peritonitis, cessation of PD, or the end of the study (December 30, 2017). The utility of IL-6AR in predicting peritonitis-free survival was analyzed using the Kaplan-Meier and Cox proportional hazards models. <b><i>Results:</i></b> A total of 149 patients were enrolled, including 72 males (48%) with mean age 52.0 ± 13.6 years and median PD duration 26 (5.9–45.5) months. During follow-up, 7,923 patient months were observed and 154 episodes of peritonitis occurred in 82 patients. Previous peritonitis episodes were significantly associated with log dialysate IL-6AR levels (β = 0.187 [0.022–0.299], <i>p</i> = 0.023). Patients in the high IL-6AR group showed a significantly inferior peritonitis-free survival when compared with their counterparts in the low IL-6AR group (48.8 vs. 67.7 months, <i>p</i> = 0.026), as well as higher treatment failure percentage of peritonitis (20.3 vs. 9.3%, <i>p</i> = 0.049). A multivariate Cox regression showed that high dialysate IL-6AR (hazard ratio [HR] 1.247 [1.052–1.478]; <i>p</i> = 0.011) and high serum C-reactive protein (HR 1.072 [1.005–1.144]; <i>p</i> = 0.036) were independent risk factors for inferior peritonitis-free survival. <b><i>Conclusion:</i></b> This prospective study suggested that the intraperitoneal inflammation marker, dialysate IL-6 level, might be a potential predictor of peritonitis development in patients undergoing PD
Supplementary Material for: Anemia Management in the China Dialysis Outcomes and Practice Patterns Study
<b><i>Background:</i></b> As the utilization of hemodialysis increases in China, it is critical to examine anemia management. <b><i>Methods:</i></b> Using data from the China Dialysis Outcomes and Practice Patterns Study (DOPPS), we describe hemoglobin (Hgb) distribution and anemia-related therapies. <b><i>Results:</i></b> Twenty one percent of China's DOPPS patients had Hgb <9 g/dl, compared with ≤10% in Japan and North America. A majority of medical directors targeted Hgb ≥11. Patients who were female, younger, or recently hospitalized had higher odds of Hgb <9; those with insurance coverage or on twice weekly dialysis had lower odds of Hgb <9. Iron use and erythropoietin-stimulating agents (ESAs) dose were modestly higher for patients with Hgb <9 compared with Hgb in the range 10-12. <b><i>Conclusion:</i></b> A large proportion of hemodialysis patients in China's DOPPS do not meet the expressed Hgb targets. Less frequent hemodialysis, patient financial contribution, and lack of a substantial increase in ESA dose at lower Hgb concentrations may partially explain this gap. Video Journal Club ‘Cappuccino with Claudio Ronco' at http://www.karger.com/?doi=442741
PowerPoint Slides for: Prognostic Value of the Delivery Dialysis Dose on Twice-Weekly Hemodialysis Patients
<p><b><i>Background:</i></b> Few studies have evaluated the prognostic
value of dialysis dose in twice-weekly hemodialysis (HD). A single-pool
Kt/V (spKt/V) over 1.70 may benefit patients receiving twice-weekly
maintenance HD. <b><i>Methods:</i></b> This is a multicenter randomized
controlled trial performed on 163 patients from 17 dialysis centers in
Shanghai who were allocated to high- (<i>n</i> = 98) and standard-dose groups (<i>n</i>
= 65) and followed through 96 weeks of study period. Therapeutic
approaches were given to increase spKt/V to over 1.70 in the high-dose
group. Data were collected every 12-24 weeks. The primary outcomes were
all-cause mortality and major adverse cardio-cerebrovascular events
(MACEs) occurrence, and secondary outcomes included residual kidney
function (RKF) and health-related quality of life (HR-QOL). <b><i>Results:</i></b> The spKt/V in high-dose and standard-dose groups were 1.80 ± 0.23 and 1.55 ± 0.19, respectively, after an 8-week intervention (<i>p</i>
< 0.001). At the end of the study, SF-36 physical function and total
score in high-dose group were 82 (69-90) and 74 (47-84), respectively,
both of which were higher than those in the standard-dose group. Decline
in urine volume was observed in both groups with no significant
difference (<i>p</i> = 0.431). No difference was found in overall survival between the 2 groups (<i>p</i> = 0.580). The 1-year MACE-free survival for high-dose group was 84.49%, better than 76.72% for standard-dose group (<i>p</i> = 0.029). <b><i>Conclusions:</i></b>
Higher spKt/V is also associated with MACE-free survival and better
HR-QOL, especially in physical function aspect for twice-weekly dialysis
patients. Increasing spKt/V over 1.70 in twice-weekly HD population
does not cause loss of RKF.</p
Supplementary Material for: Prognostic Value of the Delivery Dialysis Dose on Twice-Weekly Hemodialysis Patients
<p><b><i>Background:</i></b> Few studies have evaluated the prognostic
value of dialysis dose in twice-weekly hemodialysis (HD). A single-pool
Kt/V (spKt/V) over 1.70 may benefit patients receiving twice-weekly
maintenance HD. <b><i>Methods:</i></b> This is a multicenter randomized
controlled trial performed on 163 patients from 17 dialysis centers in
Shanghai who were allocated to high- (<i>n</i> = 98) and standard-dose groups (<i>n</i>
= 65) and followed through 96 weeks of study period. Therapeutic
approaches were given to increase spKt/V to over 1.70 in the high-dose
group. Data were collected every 12-24 weeks. The primary outcomes were
all-cause mortality and major adverse cardio-cerebrovascular events
(MACEs) occurrence, and secondary outcomes included residual kidney
function (RKF) and health-related quality of life (HR-QOL). <b><i>Results:</i></b> The spKt/V in high-dose and standard-dose groups were 1.80 ± 0.23 and 1.55 ± 0.19, respectively, after an 8-week intervention (<i>p</i>
< 0.001). At the end of the study, SF-36 physical function and total
score in high-dose group were 82 (69-90) and 74 (47-84), respectively,
both of which were higher than those in the standard-dose group. Decline
in urine volume was observed in both groups with no significant
difference (<i>p</i> = 0.431). No difference was found in overall survival between the 2 groups (<i>p</i> = 0.580). The 1-year MACE-free survival for high-dose group was 84.49%, better than 76.72% for standard-dose group (<i>p</i> = 0.029). <b><i>Conclusions:</i></b>
Higher spKt/V is also associated with MACE-free survival and better
HR-QOL, especially in physical function aspect for twice-weekly dialysis
patients. Increasing spKt/V over 1.70 in twice-weekly HD population
does not cause loss of RKF.</p